

PHARMADRUG INC.
(THE "CORPORATION")

CERTIFICATE

**Abridgement of Time Pursuant to National Instrument 54-101
*Communication with Beneficial Owners of Securities of a Reporting Issuer***

Reference is made to the annual & special meeting of shareholders of the Corporation scheduled to be held on October 13, 2023 (the "**Meeting**").

I, **Daniel Cohen, Chief Executive Officer** of the Corporation hereby certify in my capacity as an officer of the Corporation, for and on behalf of the Corporation, and not in my personal capacity, that:

1. All proxy-related materials in connection with the Meeting are being sent in compliance with the applicable timing requirements in Sections 2.9 and 2.12 of National Instrument 54-101 *Communication with Beneficial Owners of Securities of a Reporting Issuer* ("**NI 54-101**").
2. The Corporation has arranged to carry out in connection with the Meeting all of the requirements of NI 54-101 in addition to those described in item 1 above.
3. The Corporation is relying upon Section 2.20 of NI 54-101 in connection with the abridgement of certain of the time periods specified in NI 54-101 in respect of the Meeting.

The term "proxy-related materials" as used in this Certificate shall have the meaning ascribed thereto in NI 54-101.

DATED as of this 25th day of August, 2023.

PHARMADRUG INC.

By: _____



Title: Chief Executive Officer